Bone loss is a growing health care crisis, according to Texas Tech University Health Sciences Center. More than 28 million people are at high risk of developing osteoporosis, but 80 percent remain und... [Read More]
Amgen Inc has received marketing authorization from European Commission (EC) for Prolia (denosumab) to treat osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment ... [Read More]
Amgen Inc.’s bone-strengthening injection denosumab for postmenopausal women with osteoporosis will be the first biotechnology drug likely to be prescribed by patients’ primary physicians not spec... [Read More]
The U.S. Food and Drug Administration approved on Tuesday the sale of Amgen Inc's osteoporosis drug Prolia to help prevent fractures in post-menopausal women just days after the medicine received Euro... [Read More]
(Update2) Amgen Inc.’s bone-strengthening drug denosumab, the focus of the largest development program in the company’s history, was cleared by U.S. regulators for use in postmenopausal women with osteoporo... [Read More]
Federal regulators approved Amgen Inc.'s anti-osteoporosis drug, Prolia, on Tuesday for use by postmenopausal women who face a high risk of bone fractures.... [Read More]
Tuesday, The U.S. Food and Drug Administration said that it has approved Amgen Inc.'s (AMGN) Prolia, an injectable treatment for postmenopausal women with osteoporosis who are at high risk for fractur... [Read More]
UnitedProject.org Inc. (c) 2006-2010 All content published on UnitedProject.org is provided for informational purposes only and is not meant to substitute for the advice, diagnosis or treatment provided by your physician or other healthcare professionals.
If you think you are experiencing a medical problem or an emergency please contact your physician, local emergency room or call 911. Healthcare benefits and discounts are not insurance and not intended as a substitute for health insurance. Except when other source is cited, all content posted by members is licensed under Creative Commons Public Domain License.
